ADVERTISEMENT
Ipca Labs Q4 Results Review: Dolat Capital Maintains 'Add', Revises Target Price
Dolat Capital maintains ‘Accumulate’ rating at 30x FY27E P/E with a revised target price of Rs 1,604.
01 Jun 2025, 04:18 PM IST 
For FY26, Ipca Labs guided consolidated sales growth of 8-10% and Ebitda margin of 20% along with capex of Rs 4 billion.
(Source: freepik)
Dolat Capital believe that multiple triggers, such as cost efficiencies and better scaleup, are playing out in the Unichem portfolio. Additionally, the 12-13 new launches over the next two years will considerably boost the US portfolio too.
